The flash sales platform had raised $290m in venture funding, and was valued at $1bn in a SoftBank-led round in 2011.

Travel agency UTour has led a fourth funding round for the Alibaba-backed travel and tourism website by purchasing both new and existing shares.

The antibody-based drug developer has raised $77m in financing, with Merck leading its $30m series B round in 2014.

Intel will use technology developed by the drone producer, already an Intel Capital portfolio company, to beef up its RealSense drone depth-sensing system.

The Google Ventures-backed genome editing technology company has raised $163m in equity across two rounds.

Novo and Roche-backed Corvus has raised more than $108m in venture funding in just over a year and will spend the IPO proceeds on developiing its immuno-oncology therapies.

Sheffield University spinout Diurnal began trading on Aim, on Christmas eve, raising $44.6m.

Dalian Wanda is acquiring a stake of over 50% in film studio Legendary Entertainment at a valuation of up to $4bn, allowing SoftBank and Waddell & Reid to exit.

Novo and AbbVie-backed Reata plans to use the proceeds to fund a series of clinical trials for its hypertension treatments.

The oncology-focused biotechnology company, backed by Fidelity Management and Research, withdrew a previous filing in January 2015.